Home > ASQ Washington, DC &... > Special Interest Groups > BioMed/BioTech SIG Printable Version Tell a friend
2018 December Theme: Real World Evidence; US Minority Health
** 10th Year SIG Anniversary! **
12/6/18 (Thursday evening) Topic: Real World Data for Clinical Evidence Generation
12/18/18 (Tuesday evening): "United Our Vision by Working Together"
BioMed/BioTech SIG Meeting - December 18, 2018
The Opioid Crisis - Challenges and Solutions (Interagency Collaboration)
Gene-Based Solutions - Entrepreneurs' Perspective
YOUR FEEDBACKS are important to help with the continuous improvement efforts to our SIG operation, topics, speakers, and events.
If you wish to be on our SIG-event-announcement distribution list: Please email your request to C.J. George Chang at [email protected] or send text to 240-793-8425.
To provide your feedback to our Section Chairs: Please email directly to and .
To provide your feedback to our Biomed/Biotech SIG Chair: Please email directly to .
Our 200th SIG event on 11/30/17,
Our 175th SIG event on 7/7/16,
Our 150th SIG event and the 7th anniversary of our SIG on 6/18/15; and
Our 100th SIG event on 6/5/13
(Cake contributor: Mr. Arvinder Singh; photo contributor: Ms. Xiting Yang).
Our Upcoming Meeting
Our Past Events, Speakers, and Some Presentations:
Our Past Events, Speakers, and Some Presentations: continued
Our Mission and Event Themes
This Biomed/Biotech SIG was established in the second half in 2008, when global financial crisis with stock market crash occurred, leading to massive unemployment within our local communities at the Metropolitan DC.
We have wished to use this open learning/discussion platform to connect critical talents and timely local opportunities while ensured folks can continuously receive interesting but low-threshold education programs through this open forum where academia, industry, and government professionals and administrators meet, greet, network, and inspire for better practices and quality understanding.
1. To provide an open and transparent discussion and networking platform among regulatory, industry, and academic communities.
2. To facilitate truthful and honest, informed quality understanding and practices of biomedical and biotechnological research, operation, services, products, policies, and regulations.
Our Event Themes:
1. Topics on quality principles and practices to facilitate professional advancement, intellectual development, performance excellency, and organizational and personal growth.
2. For our members and interested individuals/groups within our local communities.
3. To promote effective and efficient public health services to protect public health, human and other animals alike.
Our Focus and Passion
1. To promote true understanding and practices in Quality Control, Quality Assurance, Continuous Improvement, Performance Excellence, and Sustainable Growth.
2. To facilitate inter-generation, inter-sector, inter-disciplinary, inter-cultural networking and collaboration while building focused quality teams to prepare for current and upcoming Local and Global Challenges.
3. To continue improving toward model practices for all aspects of SIG operations for our Local and Global Communities.
Our Leadership Biographies
Dr. C.J. George Chang (; 240-793-8425 (cell))
Dr. Chang is a native from Taiwan, the Republic of China (ROC), and is a veterinarian, veterinary pathologist, veterinary pharmacologist, and toxicologist by training, and a self-trained bioanalytical chemist.
From 2008-2012, Dr. Chang served as a regulatory biologist (safety reviewer) at the Division of Animal Feeds, Office of Surveillance and Compliance, Center for Veterinary Medicine (CVM), US Food and Drug Administration (FDA). He and his colleagues were responsible to regulate and review the safety of new animal-feed ingredients and assesses the health hazard of incidences of adulteration and/or misbranded animal feed products in the US. In June 2012, he joined the oncology drug review team of the Center for Drug Evaluation and Research (CDER) of FDA as a senior pharmacologist assisting premarket, nonclinical safety/efficacy review for candidate cancer drugs.
Before joining the Federal government in 2008, Dr. Chang had directed the development of biomedical products in biopharmaceutical industry, interacted with FDA and stakeholder organizations for IND submissions, and launched clinical trials; assisted in building a world-known toxicogenomics database in bioinformatic industry to predict candidate drug safety; and managed contract research projects/programs and directed non-clinical safety studies within contract research industry.
Dr. Chang earned his veterinary medicine degree from the National Taiwan University (NTU, Taiwan, ROC), his first MS in veterinary pathology on pathogenesis and animal disease diagnosis from University of Minnesota (St. Paul, MN), and his second MS and his PhD degrees in veterinary physiology/pharmacology on reproductive endocrinology, chemical carcinogenesis, and chemotherapy and chemoprevention for human cancers from The Ohio State University (Columbus, OH). He spent three years afterward conducting postdoctoral research with focus on molecular dosimetry of high impact carcinogens, quantified critical molecular biomarkers, and assessed chemo-preventive potential of candidate drugs for tobacco-specific nitrosamine-induced toxicities in animal models at a Wake Forest University/RJR Tobacco joined postdoc training program (Leon Goldberg Fellowship; Winston-Salem, NC).
Dr. Chang's career goals are to assess the efficacy/utility and safety of candidate biomedical products, to facilitate collaboration within scientific community, and to provide pertinent information protecting and promoting the health of general public. He is board-certified as a general toxicologist (DABT), quality auditor (CQA), regulatory affairs specialist (RAC), and project management profession (PMP).
Becoming Winning Team-Players and Leaders in Biomed/Biotech Sectors!
Why and How We Have Successfully Built A Biomed/Biotech SIG?